Power Calculations for Clinical Trials in Alzheimer's Disease

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2011 Oct 6

PMID 21971476

Citations 45

Authors

M Colin Ard

Steven D Edland

Affiliations

Soon will be listed here.

Abstract

The Alzheimer research community is actively pursuing novel biomarker and other biologic measures to characterize disease progression or to use as outcome measures in clinical trials. One product of these efforts has been a large literature reporting power calculations and estimates of sample size for planning future clinical trials and cohort studies with longitudinal rate of change outcome measures. Sample size estimates reported in this literature vary greatly depending on a variety of factors, including the statistical methods and model assumptions used in their calculation. We review this literature and suggest standards for reporting power calculation results. Regardless of the statistical methods used, studies consistently find that volumetric neuroimaging measures of regions of interest, such as hippocampal volume, outperform global cognitive scales traditionally used in clinical treatment trials in terms of the number of subjects required to detect a fixed percentage slowing of the rate of change observed in demented and cognitively impaired populations. However, statistical methods, model assumptions, and parameter estimates used in power calculations are often not reported in sufficient detail to be of maximum utility. We review the factors that influence sample size estimates, and discuss outstanding issues relevant to planning longitudinal studies of Alzheimer's disease.

Citing Articles

Reliability of structural brain change in cognitively healthy adult samples.

Vidal-Pineiro D, Sorensen O, Stromstad M, Amlien I, Anderson M, Baare W bioRxiv. 2025; .

PMID: 40027710 PMC: 11870432. DOI: 10.1101/2024.06.03.592804.

Factors Influencing Outcome After Shoulder Arthroplasty (FINOSA Study): Protocol of a Prospective Longitudinal Study With Randomized Group Allocation.

Claes A, De Mesel A, Struyf T, Verborgt O, Struyf F JMIR Res Protoc. 2024; 13:e56522.

PMID: 39556824 PMC: 11612598. DOI: 10.2196/56522.

Assessing Alzheimer's disease via plasma extracellular vesicle-derived mRNA.

Pham L, Chang C, Tuchez K, Liu F, Chen Y Alzheimers Dement (Amst). 2024; 16(3):e70006.

PMID: 39279994 PMC: 11399882. DOI: 10.1002/dad2.70006.

Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development.

Moyer H, Mellett R, Vigneault K, McKeown M, Karlawish J, Augustine E Neurology. 2024; 103(1):e209533.

PMID: 38833654 PMC: 11226307. DOI: 10.1212/WNL.0000000000209533.

Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.

Mendes A, Ribaldi F, Lathuiliere A, Ashton N, Zetterberg H, Abramowicz M Alzheimers Res Ther. 2024; 16(1):110.

PMID: 38755703 PMC: 11097559. DOI: 10.1186/s13195-024-01478-9.

References

Nestor S, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells J . Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain. 2008; 131(Pt 9):2443-54. PMC: 2724905. DOI: 10.1093/brain/awn146. View

Stein J, Hua X, Lee S, Ho A, Leow A, Toga A . Voxelwise genome-wide association study (vGWAS). Neuroimage. 2010; 53(3):1160-74. PMC: 2900429. DOI: 10.1016/j.neuroimage.2010.02.032. View

ROSEN W, Mohs R, Davis K . A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141(11):1356-64. DOI: 10.1176/ajp.141.11.1356. View

Ho A, Stein J, Hua X, Lee S, Hibar D, Leow A . A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A. 2010; 107(18):8404-9. PMC: 2889537. DOI: 10.1073/pnas.0910878107. View

Schlesselman J . Planning a longitudinal study. II. Frequency of measurement and study duration. J Chronic Dis. 1973; 26(9):561-70. DOI: 10.1016/0021-9681(73)90061-1. View

Holland D, Brewer J, Hagler D, Fennema-Notestine C, Fenema-Notestine C, Dale A . Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009; 106(49):20954-9. PMC: 2791580. DOI: 10.1073/pnas.0906053106. View

Wolz R, Heckemann R, Aljabar P, Hajnal J, Hammers A, Lotjonen J . Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI. Neuroimage. 2010; 52(1):109-18. DOI: 10.1016/j.neuroimage.2010.04.006. View

Aisen P, Andrieu S, Sampaio C, Carrillo M, Khachaturian Z, Dubois B . Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2010; 76(3):280-6. PMC: 3034393. DOI: 10.1212/WNL.0b013e318207b1b9. View

Leung K, Barnes J, Ridgway G, Bartlett J, Clarkson M, MacDonald K . Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage. 2010; 51(4):1345-59. PMC: 2873209. DOI: 10.1016/j.neuroimage.2010.03.018. View

10.

Leung K, Clarkson M, Bartlett J, Clegg S, Jack Jr C, Weiner M . Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage. 2009; 50(2):516-23. PMC: 2828361. DOI: 10.1016/j.neuroimage.2009.12.059. View

11.

Chen K, Langbaum J, Fleisher A, Ayutyanont N, Reschke C, Lee W . Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage. 2010; 51(2):654-64. PMC: 2856742. DOI: 10.1016/j.neuroimage.2010.02.064. View

12.

Morra J, Tu Z, Apostolova L, Green A, Avedissian C, Madsen S . Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp. 2009; 30(9):2766-88. PMC: 2733926. DOI: 10.1002/hbm.20708. View

13.

Mueller S, Weiner M, Thal L, Petersen R, Jack C, Jagust W . Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2007; 1(1):55-66. PMC: 1864941. DOI: 10.1016/j.jalz.2005.06.003. View

14.

Schuff N, Woerner N, Boreta L, Kornfield T, Shaw L, Trojanowski J . MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009; 132(Pt 4):1067-77. PMC: 2668943. DOI: 10.1093/brain/awp007. View

15.

Weiner M, Aisen P, Jack Jr C, Jagust W, Trojanowski J, Shaw L . The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010; 6(3):202-11.e7. PMC: 2927112. DOI: 10.1016/j.jalz.2010.03.007. View

16.

Vozdolska R, Sano M, Aisen P, Edland S . The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009; 6(2):126-32. PMC: 2864093. DOI: 10.1177/1740774509103485. View

17.

Yushkevich P, Avants B, Das S, Pluta J, Altinay M, Craige C . Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage. 2009; 50(2):434-45. PMC: 2823935. DOI: 10.1016/j.neuroimage.2009.12.007. View

18.

Aisen P, Schneider L, Sano M, Diaz-Arrastia R, van Dyck C, Weiner M . High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008; 300(15):1774-83. PMC: 2684821. DOI: 10.1001/jama.300.15.1774. View

19.

Kraemer H, Mintz J, Noda A, Tinklenberg J, Yesavage J . Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006; 63(5):484-9. DOI: 10.1001/archpsyc.63.5.484. View

20.

Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Zhang H . The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010; 6(3):257-64. PMC: 2867839. DOI: 10.1016/j.jalz.2010.03.002. View